DeepMed Research

Celltrion Inc

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Established: 1999-01-01

Employees: -

Market Cap: $31.9B

Website: http://www.celltrion.com/

Clinical Trials

To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: CT-P17
Biological: EU-approved Humira
Biological: US-licensed Humira

First Posted Date: 2019-06-03

Last Posted Date: 2021-11-18

Lead Sponsor: Celltrion

Target Recruit Count: 312

Registration Number: NCT03970824

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷
Severance Hospital, Seoul, Korea, Republic of

and more 6 locations

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: CT-P13 SC (Infliximab)
Other: Placebo SC

First Posted Date: 2019-05-10

Last Posted Date: 2023-10-23

Lead Sponsor: Celltrion

Target Recruit Count: 396

Registration Number: NCT03945019

Locations: 🇺🇸
Biopharma Informatic - Houston, Houston, Texas, United States
🇨🇿
Fakultni nemocnice Ostrava, Ostrava, Czechia
🇫🇷
Centre Hospitalier Lyon Sud, Pierre-Bénite, France

and more 26 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CT-G20 Placebo
Drug: CT-G11 Placebo
Drug: CT-G11
Drug: CT-G20

First Posted Date: 2019-04-18

Last Posted Date: 2020-06-09

Lead Sponsor: Celltrion

Target Recruit Count: 72

Registration Number: NCT03918967

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: CT-P17 SC
Biological: Humira SC

First Posted Date: 2018-12-28

Last Posted Date: 2021-11-17

Lead Sponsor: Celltrion

Target Recruit Count: 648

Registration Number: NCT03789292

Locations: 🇧🇬
National Multiprofile Transport Hospital Tsar Boris III, Sofia, Bulgaria

To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: CT-P13
Biological: Remicade

First Posted Date: 2018-10-16

Last Posted Date: 2021-09-14

Lead Sponsor: Celltrion

Target Recruit Count: 270

Registration Number: NCT03707535

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Adenocarcinoma of Lung

Interventions: Drug: CT-P16
Drug: Avastin

First Posted Date: 2018-09-18

Last Posted Date: 2025-03-17

Lead Sponsor: Celltrion

Target Recruit Count: 689

Registration Number: NCT03676192

Locations: 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection

Phase 2

Terminated

Conditions: Influenza A

Interventions: Drug: CT-P27 90 mg/kg
Drug: CT-P27 45 mg/kg
Drug: Placebo

First Posted Date: 2018-04-27

Last Posted Date: 2022-10-31

Lead Sponsor: Celltrion

Target Recruit Count: 228

Registration Number: NCT03511066

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

Phase 1

Completed

Conditions: Health, Subjective

Interventions: Biological: CT-P13 SC Auto-injector
Biological: CT-P13 SC Pre-filled Syringe

First Posted Date: 2018-02-27

Last Posted Date: 2019-07-26

Lead Sponsor: Celltrion

Target Recruit Count: 218

Registration Number: NCT03446976

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CT-P16
Drug: US-licensed Avastin
Drug: EU-approved Avastin

First Posted Date: 2017-08-14

Last Posted Date: 2020-03-26

Lead Sponsor: Celltrion

Target Recruit Count: 141

Registration Number: NCT03247673

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
🇰🇷
Seoul St.Mary's hospital, Seoul, Korea, Republic of

A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: CT-P13

First Posted Date: 2017-05-10

Last Posted Date: 2020-04-08

Lead Sponsor: Celltrion

Target Recruit Count: 407

Registration Number: NCT03147248

Locations: 🇰🇷
Hanyang University Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy